Purple Biotech (PPBT) Liabilities and Shareholders Equity (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $14.4 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 59.5% year-over-year to $14.4 million in Q1 2026; TTM through Mar 2026 was $105.4 million, a 26.69% decrease from a year earlier, with the FY2025 full-year figure at $17.6 million, down 52.56% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $14.4 million, down from $17.6 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for PPBT reached as high as $66.3 million in Q1 2022 and fell as low as $14.4 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $42.4 million across 5 years, with a median of $39.9 million in 2024.
• Across the five-year window, Liabilities and Shareholders Equity increased 11.27% in 2025 and sank 59.5% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $54.6 million in 2022, then dropped by 18.89% to $44.3 million in 2023, then slipped by 16.4% to $37.0 million in 2024, then slumped by 52.56% to $17.6 million in 2025, then decreased by 17.95% to $14.4 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $14.4 million in Q1 2026, $17.6 million in Q4 2025, and $39.1 million in Q3 2025.